The takeaway
Monopar Therapeutics Inc shows a pronounced seasonal pattern over 7 years of data — strongest in October (+34.5%) and softest in August (−15.5%).
Right now
In July, the stock has fallen 33% of years, averaging −2.6%, roughly 4.7 pts behind the S&P 500.
The full picture
Monopar Therapeutics Inc's most dependable month has been October, higher in 4 of 6 years; August has been its least reliable, up just 0% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | ||||||||||||
| 2020 | ||||||||||||
| 2019 | — | — | — | — | — | — | — | — | — | — | — |
Month by month
The stock's clearest edge over the S&P 500 lands in September (+49.9 pts); it has trailed the market most in March (−20.7 pts).
“vs S&P” is Monopar Therapeutics Inc’s average for a month minus the S&P 500’s average for that same month — isolating Monopar Therapeutics Inc’s own seasonal edge from broad market drift.
Reality check
Over the last 5 years, October has closed higher 80% of the time versus 67% across the last 7 years — the pattern is strengthening.
Figures are the typical (median) October return and how often it rose — the last 5 years versus the last 7(the heatmap’s default window). This verdict stays anchored to that 7-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
October looks the standout, up in 4 of 6 Octobers — yet the appeal is lumpy, leaning on the occasional blow-out year rather than dependable strength.
The headline flatters a touch — its +34.5% average sits well above the +3.0% a typical year delivers, the work of a few big Octobers. That reliability comes with real swings, mind — even October ranges by 72.7% from year to year, so any single year can land far from the average. Crucially, the gain is the stock's own rather than a rising tide's: October has cleared the S&P 500 by +33.4 points above the index. That consistency sets it apart from the field, where the average stock manages October only about 53% of the time.
On the other side of the ledger, August has been the soft spot — the weakest of 6 months that average a loss (−15.5%), and the edge isn't year-round — the stock has trailed the S&P 500 in March, August, and December. Its roughest month on record was a −50.2% March in 2023 — a reminder of how hard even a seasonal name can fall.
If anything it has sharpened recently — the last five Octobers run ahead of the earlier years.
Hold it loosely, then: the October tendency is genuine but lumpy, more about the occasional outsized year than a gain to bank on. With a short 7-year record and returns that swing hard year to year, the signal is best held loosely.
Short answers on the stock's best month (October), its worst (August), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2019 its best month (October, +34.5%) has run well ahead of its worst (August, −15.5%) — the heatmap above shows how steady that gap has been year to year.
October has been the strongest, averaging +34.5% and closing higher in 4 of 6 years since 2019.
It's the weakest, averaging −15.5% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade